Discover Our Group:

Berlin-Chemie has been developing, manufacturing and distributing pharmaceutical products for over 130 years and has been a wholly owned subsidiary of the Menarini Group, the leading Italian pharmaceutical company, since 1992. 

Responsibility is a top priority at Berlin-Chemie. We not only make an important contribution to healthcare, but also put our values into practice through various social initiatives.

Discover More about Global Responsibility

From school kits to free meals and medicines, to caring for the environment around the world. In Menarini, being responsible means translating our values into concrete actions that are good for others and good for the planet

Berlin-Chemie – a strong partner. Our many years of experience and the success of joint projects make us the partner of choice. 

Discover More about Global Partnering

Menarini has in-depth know-how in many important therapeutic areas, thanks to many years of excellent market introduction, marketing and sales capabilities as well as expertise in regulatory aspects and market access. Collaboration is the key to great success, and at Menarini, partnership is part of the DNA.

Our holistic and professional health management offers doctors individual counselling, training or workshops, events and lectures on many topics, depending on their needs.

Our Medical Hub acts as a central point of contact for doctors and healthcare professionals. Here you will find all the information about our medications, additional service and training opportunities.

Welcome to the News & More section. Here you will find general information in the form of press releases, news and the latest graphical material. 

Menarini Blog

Follow Us

We employ professionals with a wide variety of career backgrounds and are employers who care about their staff. Together, we stand for innovation and reliability.

Our Job Portal

Find out about our current vacancies at Berlin-Chemie directly on our career portal.

Menarini Group News

2010 - 03 - 02

The Menarini Group lands in a New Continent

Florence, 2nd March, 2010

The Menarini Group lands in a New Continent

The Menarini Pharmaceutical Group has expanded its territorial coverage to include Australia by entering into a licensing agreement with CSL Biotherapies, Australian pharmaceutical company, for the provision of one of its prime products.

The product in question is Nebivolol, a cardio-selective, third generation beta-blocker, characterised by the capability to release nitric oxide. Nebivolol, a molecule developed by Menarini Research, suitable for the treatment of heart failure, is currently marketed in 72 countries.

In Australia there are 300.000 patients currently suffering from heart failure and 30.000 new cases are diagnosed each year.

The effect of Nebivolol was the subject of an in-depth study carried out by Nobel prize winner for Medicine, Luis Ignarro, who demonstrated the mechanism by which the nitric oxide in Nebivolol works, making it a ‘one in a kind’ drug.

The ‘Seniors’ study on the other hand has proven how the efficacy of Nebivolol, in the case of heart failure, is able to reduce the overall mortality rate due to cardiovascular conditions by 14%, and the number of cases of sudden death in patients affected by this condition by 39%.

It is thanks to qualities such as these that Nebivolol has earned itself a unique place in the new European Guidelines, where its distinguishing features compared to other beta-blockers have been highlighted, both in terms of efficacy and patient safety.